Mylan Wins Costs After Neurim Drops EU Patent Appeal

By Bonnie Eslinger (March 15, 2021, 6:56 PM GMT) -- After initially losing a bid to invalidate an insomnia drug patent, Mylan was dubbed the winner and convinced a London judge to award costs after Neurim Pharmaceuticals abandoned its bid to defend its claim in parallel European Patent Office litigation.

High Court Judge Marcus Smith said in light of the outcome at the EPO, Mylan is also the "obvious" winner in the case before his court, making Neurim Pharmaceuticals Ltd. "the loser."

Mylan had challenged the validity of the patent in litigation brought by Neurim, which sells the insomnia medication under the brand name Circadin. On Dec. 4, Judge Smith concluded...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!


Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!